Acute Myeloid Leukemia

10 targeted therapies for Acute Myeloid Leukemia(AML)

The main targeted therapies for Acute Myeloid Leukemia (AML) include: FLT3 inhibitors For AML with FLT3 mutations, such as midostaurin, gilteritinib, etc. These target the FLT3 tyrosine kinase. Midostaurin[1] On April 28, 2017, the U.S. Food and Drug Administration approved midostaurin (RYDAPT, Novartis Pharmaceuticals Corp.) for the treatment of adult patients with newly diagnosed acute myeloid leukemia…